TRABD inhibitors are a class of chemical compounds designed to specifically target the TRABD protein, a member of the TRAB domain-containing family, and inhibit its biological function. These inhibitors typically bind to the active site of the TRABD protein, where they prevent its natural substrates or ligands from interacting with the protein. This inhibition blocks the normal biochemical processes facilitated by TRABD, altering the protein's role in cellular pathways. In some cases, TRABD inhibitors can bind to allosteric sites on the protein, which are located away from the active site. By binding to these allosteric regions, inhibitors can induce conformational changes in the protein, leading to a decrease or cessation of its functional activity. The interaction between TRABD inhibitors and the protein is mediated by various non-covalent forces, such as hydrogen bonding, hydrophobic contacts, van der Waals forces, and electrostatic interactions, which stabilize the inhibitor-protein complex and ensure effective inhibition.
The structural design of TRABD inhibitors is highly diverse, allowing for flexibility in their interaction with different regions of the TRABD protein. These inhibitors often incorporate functional groups like hydroxyl, amine, or carboxyl groups, which facilitate specific interactions with key residues within the TRABD protein's binding pocket. Aromatic rings and heterocyclic structures are frequently present in these inhibitors to enhance hydrophobic interactions with non-polar regions of the protein, increasing their binding affinity. Additionally, the physicochemical properties of TRABD inhibitors, such as molecular weight, lipophilicity, solubility, and polarity, are optimized to ensure stability and effectiveness in various biological environments. Hydrophobic regions within the inhibitor may interact with non-polar regions of the protein, while polar groups enhance solubility and promote hydrogen bonding with polar residues in the TRABD protein. By balancing these structural and physicochemical properties, TRABD inhibitors can be fine-tuned to achieve specific and effective modulation of the protein's activity in different biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Binds to DNA and inhibits transcription elongation by RNA polymerase, potentially decreasing expression of "TraB domain containing". | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Inhibits RNA polymerase II, which could lead to reduced mRNA synthesis and lower levels of "TraB domain containing" protein. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Alters transcriptional activity, potentially reducing the expression of the "TraB domain containing" protein. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Shortens RNA poly(A) tails, possibly decreasing mRNA stability and expression of "TraB domain containing". | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibits RNA polymerase II activation, potentially decreasing "TraB domain containing" protein levels. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Induces mutations in RNA and DNA, possibly leading to decreased expression of "TraB domain containing" protein. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Forms DNA crosslinks, potentially preventing transcription and reducing "TraB domain containing" protein expression. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Intercalates DNA and interferes with topoisomerase II, potentially reducing expression of "TraB domain containing". | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Inhibits DNA topoisomerase I, potentially leading to decreased transcription of the "TraB domain containing" gene. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Inhibits translation initiation, which could reduce the levels of "TraB domain containing" protein. | ||||||